Conno Christou doesn’t leave things to chance. He tracks his sleep with a Whoop band, cross-references it with an Oura ring, and gets nearly 100 biomarkers checked every year. He had been doing the annual bloodwork for four consecutive years, following the protocols of longevity researchers like Peter Attia and Rhonda Patrick. He optimized his supplements, his circadian rhythm, his protein intake.
At 35, building his second company, he was as dialed-in on the latest in health research as anyone he knew. His last checkup, in 2025, was green across the board. “It was the best I’d had in years,” he says.
Then, after a workout, his arm swelled.
He didn’t think much of it at first. A week passed before he saw a doctor, who found two blood clots in his veins and scheduled surgery. But the pre-op exams changed everything. A doctor walked back into the room and told him the procedure wasn’t happening.
“We see an 11-by-11-by-8 centimeter mass behind your sternum,” the doctor said.
A biopsy confirmed what Christou had never even contemplated. He had an aggressive, fast-growing form of non-Hodgkin’s lymphoma — a rare diagnosis affecting roughly one in 420,000 people, caused by a random genetic mutation with no connection to lifestyle, diet, or stress.
The tumor had only existed for about three months. In three more weeks, it would have reached stage four.
“Lucky in my unluckiness,” Christou told this editor from his home in Athens, where he lives part time. “It was only found because I went in for something else entirely.”
What followed was an education in the limits of the medical system — and in what a determined patient can do about it with tools now available, including artificial intelligence. By 2026, AI-powered second-opinion platforms and clinical decision support tools are becoming more common, helping patients like Christou navigate complex treatment options.
His first oncologist, a renowned specialist, recommended the lighter of two available chemotherapy regimens. Christou booked his first infusion three days out. Then, the night before, he sought a second opinion.
That second doctor didn’t hesitate. He recommended the harder regimen — continuous in-hospital infusion, cycling every three weeks over six months — citing Christou’s specific pathology. The lighter treatment carried roughly a 60% success rate for his presentation. The aggressive one brought that number to around 85%. Two world-class doctors. Diametrically opposite recommendations.
“As founders, we hold the wheel,” Christou says of the propensity of many people to accept what they are told — and why more should not. “You hear many things. You don’t have to follow the first advice.”
He didn’t just follow the second physician’s advice either. Over the next two days, he gathered 12 opinions in total — drawing on his professional network, reaching out to hematologists and oncologists in the US and abroad, and calling in every favor he could. Eleven to one voted for the harder path. He took it. The decision, he says, didn’t feel brave so much as logical. He was already a data-driven person, and now the stakes felt existential.
In 2026, AI tools can accelerate this process. Platforms like "SecondOpinion AI" and "Oncora Medical" use machine learning to analyze patient pathology data against thousands of comparable cases, helping patients and doctors identify the most effective treatment protocols in minutes rather than days. Christou didn't use these tools directly, but his approach mirrors their logic: gather diverse inputs, weigh probabilities, and act on the best evidence.
Over six months of treatment, Christou approached chemotherapy the way he approached building a company: as a marathon of sprints, each with a finite cycle and every week filled with data points. He had completed a mandatory 25-month military service in Cyprus at age 18, and he borrowed the discipline from that experience — tracking his blood counts, adjusting his diet in real time, and using a custom AI chatbot he built to synthesize medical research papers into actionable insights for his care team.
“I treated my body like a startup,” he says. “I had the mission, the metrics, and the team. I just needed the right strategy.”
By early 2026, Christou is in remission. He continues to monitor his health obsessively, but now with a deeper appreciation for the fragility of even the most optimized biology. He’s also become an advocate for patient-driven healthcare, speaking at conferences about the importance of questioning authority and leveraging technology — including AI — to make life-or-death decisions.
“The fittest founder in the room still gets cancer,” he says. “But the one who uses every tool available — including his network and the latest tech — has a better shot at fighting back.”
via TechCrunch AI